[EN] PROCESS FOR PREPARING 1 -(((Z)-(1 -(2-AMINOTHIAZOL-4-YL)-2-OXO-2-(((3S,4R)-2-OXO-4-((2-OXOOXAZOLIDIN-3-Y L)METHYL)-1 -SULFOAZETIDIN-3- YL)AMINO)ETHYLIDENE)AMINO)OXY)CYCLOPROPANE CARBOXYLIC ACID [FR] PROCESSUS CHIMIQUE DE PRÉPARATION D'ANTIBIOTIQUE MONOBACTAME ET DE SES INTERMÉDIAIRES
[EN] PROCESS FOR PREPARING 1 -(((Z)-(1 -(2-AMINOTHIAZOL-4-YL)-2-OXO-2-(((3S,4R)-2-OXO-4-((2-OXOOXAZOLIDIN-3-Y L)METHYL)-1 -SULFOAZETIDIN-3- YL)AMINO)ETHYLIDENE)AMINO)OXY)CYCLOPROPANE CARBOXYLIC ACID [FR] PROCESSUS CHIMIQUE DE PRÉPARATION D'ANTIBIOTIQUE MONOBACTAME ET DE SES INTERMÉDIAIRES
Insights into the Role of Graphitic Carbon Nitride as a Photobase in Proton‐Coupled Electron Transfer in (sp
<sup>3</sup>
)C−H Oxygenation of Oxazolidinones
Transformation of oxazolidinones to corresponding oxazolidine-2,4-diones is enabled by mpg-CN, a carbonnitride photocatalyst, using oxygen gas as an oxidant. The reaction proceeds via proton-coupled electrontransfer. The mechanism of this transformation is established by photocatalytic experiments, transient absorption spectroscopy and DFT calculations.
Addition of glycinate enolate equivalents to 1,4-benzodiazepine imino phosphates. Preparation of synthetically useful 2-(ethyl glycinat-.alpha.-ylidene)-1,4-benzodiazepines and related derivatives
作者:R. Ian Fryer、Linas V. Kudzma、Zi Qiang Gu、Kuei Ying Lin、P. White Rafalko
DOI:10.1021/jo00011a051
日期:1991.5
FRYER, R. IAN;KUDZMA, LINAS V.;GU, ZI-QIANG;LIN, KUEI-YING;RAFALKO, P. WH+, J. ORG. CHEM., 56,(1991) N1, C. 3715-3719
作者:FRYER, R. IAN、KUDZMA, LINAS V.、GU, ZI-QIANG、LIN, KUEI-YING、RAFALKO, P. WH+
DOI:——
日期:——
CHEMICAL PROCESS FOR MANUFACTURING MONOBACTAM ANTIBIOTIC AND INTERMEDIATES THEREOF
申请人:Novartis AG
公开号:US20200239461A1
公开(公告)日:2020-07-30
The present invention provides a process of synthesizing 1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3 yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid (referred to herein as Compound X), or a salt thereof, or a solvate including hydrate thereof, and/or intermediates thereof, and the use of intermediates for preparing Compound X. In particular, the process relates to the preparation of Compound X using dynamic kinetic resolution (DKR) and asymmetric catalytic reduction, thereby providing an improved route to 1-(((Z)-(1-(2-aminothiazol-4-yl)-2-oxo-2-(((3S,4R)-2-oxo-4-((2-oxooxazolidin-3-yl)methyl)-1-sulfoazetidin-3 yl)amino)ethylidene)amino)oxy)cyclopropanecarboxylic acid (Compound X) and compositions containing said compound, including the arginine salt, sodium salt and hydrated solid forms of Compound X.